By Conor Hale
Caris Life Sciences has tapped ConcertAI for a joint pitch to cancer researchers, clinicians and drug developers.
The pairing will see Caris’ silo of real-world patient information—including DNA, RNA and protein data, as well as the sequencing of tumor mutations—merge with ConcertAI’s collection of cases spanning solid tumors and blood cancers, including the treatment and outcomes of nearly 7 million patients.
The goal is to provide oncology researchers with a reference platform for translational work, and services that aid in the design of clinical trials to test out potential new drugs—including first-in-human studies and approaches to patients whose cancers have grown resistant to current therapies.
Though the financial terms have not been disclosed, the companies said in a release that the two would “align their scientific talent” as well as their artificial intelligence-powered software-as-a-service offerings, aimed at academic and biopharma customers.
During the J.P. Morgan Healthcare Conference in San Francisco, ConcertAI also highlighted its recent work with Bristol Myers Squibb on a separate digital solution for oncology trials and clinical site management.
The company said the program moved into randomized phase 2 and 3 trials in August 2022 and has been used to help integrate lab results, genomic findings and imaging scans. This year, ConcertAI plans to expand its US trial network with programs for matching patients to clinical studies and automating research tasks.
The Ten West Link Transmission Line is an infrastructure project covered under Title 41 of the FAST Act (FAST-41). Through the Federal Permitting Improvement Steering Council, the BLM coordinated reviews with other agencies, including the National Park Service, US Fish and Wildlife Service, Advisory Council on Historic Preservation, Council on Environmental Quality, Department of Defense, as well as Tribal leadership and local communities, to make a timely and informed project decision
